… rituximab, is an alternative therapy for relapsing and refractory systemic lupus erythematosus.
We sought to assess the long-term efficacy and safety of rituximab in this patient subgroup. …

… We describe safety data from an international rituximab RA clinical trial … safety report of
rituximab in RA to date and greatly increases the power to detect common and rare safety risks …

… study assessing the long-term safety and efficacy of rituximab in ITP and … rituximab have
undergone retreatment, our study also gives data regarding the safety and efficacy of rituximab …

… Final evaluation of the longterm safety of rituximab (RTX) in rheumatoid arthritis (RA) up to
… No new safety risks were identified and there was no increase in the rate of any types of …

Objectives To assess efficacy and safety of rituximab (RTX) as induction therapy,
maintenance of remission and treatment of relapses in a cohort of IgG4-related disease (IgG4-RD) …

… usually include safety results for only Aim: To evaluate the long-term safety of rituximab in …
patients with rheumatoid arthritis treated with rituximab and followed-up for longer than 1 year. …

… Conclusions This analysis demonstrates that rituximab remains generally well tolerated
over time and multiple courses, with a safety profile consistent with published data and clinical …

… This study shows long‐term safety data for 989 patients with RA who were treated with
rituximab. The study provides extensive characterizations of clinically relevant infections, CVT …

… Long-term safety data on rituximab are limited. The objectives of this study were to evaluate
the long-term safety and tolerability of rituximab … years treated with rituximab for SIADs was …

… RTX is effective and safe in Caucasian NMOSD patients, even after a long-term follow-up. …
Our results supported recent reports about the short-term efficacy of RTX in NMO 12–18 and …